Ketamine
- PDF / 169,239 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 75 Downloads / 192 Views
1 S
Hypertension following off label use: case report In a retrospective study of 203 patients, who received IV ketamine infusions at a treatment centre in Canada, between August 2018 and December 2019, one patient [age and sex not stated] was described, who developed hypertension following off label treatment with ketamine for treatment resistant depression [duration of treatment to reaction onset and outcome not stated]. The patient with treatment resistant depression started receiving off label therapy with IV ketamine infusions. The patient was scheduled to receive four ketamine infusions; first two ketamine infusions were dosed at 0.5 mg/kg (exact doses of next two infusions not stated). The ketamine was diluted in sodium-chloride [0.9% saline solution] and administered over 40 to 45 minutes. During the treatment, the patient developed hypertension. The patient received treatment with amlodipine. Rodrigues NB, et al. Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. 803496947 Expert Opinion on Drug Safety : 1-10, Jan 2020. Available from: URL: http://doi.org/10.1080/14740338.2020.1776699
0114-9954/20/1818-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 22 Aug 2020 No. 1818
Data Loading...
